Opko Health CEO Acquires $90,600 in Stock (OPK)
Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost acquired 10,000 shares of the company’s stock on the open market in a transaction dated Tuesday, August 19th. The stock was purchased at an average price of $9.06 per share, for a total transaction of $90,600.00. Following the acquisition, the chief executive officer now directly owns 2,012,377 shares in the company, valued at approximately $18,232,136. The purchase was disclosed in a document filed with the SEC, which is available at this link.
Several analysts have recently commented on the stock. Analysts at Jefferies Group reiterated a “buy” rating on shares of Opko Health in a research note on Wednesday, August 13th. They now have a $10.50 price target on the stock, down previously from $11.00. Finally, analysts at TheStreet upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Friday, May 30th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $12.00.
Opko Health (NYSE:OPK) opened at 8.82 on Friday. Opko Health has a one year low of $7.32 and a one year high of $12.95. The stock’s 50-day moving average is $8.92 and its 200-day moving average is $8.82. The company’s market cap is $3.785 billion.
Opko Health (NYSE:OPK) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.03. The company had revenue of $23.50 million for the quarter, compared to the consensus estimate of $23.70 million. During the same quarter in the previous year, the company posted ($0.01) earnings per share. The company’s revenue for the quarter was down 1.3% on a year-over-year basis. Analysts expect that Opko Health will post $-0.31 EPS for the current fiscal year.
OPKO Health, Inc (NYSE:OPK) is a multi-national biopharmaceutical and diagnostics company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.